Tower Research Capital LLC (TRC) - BIOXCEL THERAPEUTICS INC ownership

BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 75 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 4.00 and the average weighting 0.0%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of BIOXCEL THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$15,452
+18.4%
12,072
+160.9%
0.00%
Q1 2024$13,048
-68.0%
4,627
-66.5%
0.00%
-100.0%
Q4 2023$40,804
+295.5%
13,832
+239.2%
0.00%
Q3 2023$10,318
-72.7%
4,078
-28.2%
0.00%
-100.0%
Q2 2023$37,823
+130324.1%
5,679
+271.4%
0.00%0.0%
Q1 2023$29
+163.6%
1,529
+205.2%
0.00%
Q4 2022$11
-99.9%
501
-59.9%
0.00%
Q3 2022$15,000
-57.1%
1,250
-52.4%
0.00%
-100.0%
Q2 2022$35,000
-49.3%
2,628
-20.8%
0.00%0.0%
Q1 2022$69,000
-27.4%
3,317
-29.3%
0.00%
-50.0%
Q4 2021$95,000
-33.6%
4,690
+0.1%
0.00%
-50.0%
Q3 2021$143,000
+521.7%
4,686
+475.0%
0.00%
+300.0%
Q2 2021$23,000
-68.9%
815
-52.5%
0.00%0.0%
Q1 2021$74,000
+1750.0%
1,716
+1850.0%
0.00%
Q4 2020$4,000
-94.8%
88
-95.0%
0.00%
-100.0%
Q3 2020$77,000
-75.6%
1,770
-70.3%
0.00%
-92.3%
Q2 2020$316,000
+10433.3%
5,963
+4910.9%
0.01%
Q1 2020$3,000
-66.7%
119
-90.8%
0.00%
-100.0%
Q3 2019$9,000
+125.0%
1,291
+243.4%
0.00%
Q2 2019$4,0000.0%376
-66.5%
0.00%
Q4 2018$4,000
+100.0%
1,122
+247.4%
0.00%
Q3 2018$2,000
+100.0%
323
+223.0%
0.00%
Q1 2018$1,0001000.00%
Other shareholders
BIOXCEL THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Logos Global Management LP 430,000$19,866,0001.70%
APIS CAPITAL ADVISORS, LLC 20,000$924,0000.89%
Avidity Partners Management LP 547,000$25,271,0000.82%
Knoll Capital Management, LLC 20,000$924,0000.63%
Artemis Investment Management LLP 1,013,448$46,839,0000.49%
AlphaCentric Advisors LLC 25,000$1,155,0000.48%
First Light Asset Management, LLC 94,202$4,352,0000.32%
Ikarian Capital, LLC 150,000$6,930,0000.31%
Longitude (Cayman) Ltd. 8,000$370,0000.18%
AllSquare Wealth Management LLC 5,490$254,0000.17%
View complete list of BIOXCEL THERAPEUTICS INC shareholders